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Schjerning J, Uhrenholt TR, Svenningsen P, Vanhoutte PM, Skøtt
O, Jensen BL, Hansen PB. Histamine-dependent prolongation by aldo-
sterone of vasoconstriction in isolated small mesenteric arteries of the
mouse. Am J Physiol Heart Circ Physiol 304: H1094–H1102, 2013. First
published February 8, 2013; doi:10.1152/ajpheart.00524.2012.—In arte-
rioles, aldosterone counteracts the rapid dilatation (recovery) follow-
ing depolarization-induced contraction. The hypothesis was tested that
this effect of aldosterone depends on cyclooxygenase (COX)-derived
products and/or nitric oxide (NO) synthase (NOS) inhibition. Recov-
ery of the response to high K was observed in mesenteric arteries of
wild-type and COX-2/ mice but it was significantly diminished in
preparations from endothelial NOS (eNOS)/ mice. Aldosterone
pretreatment inhibited recovery from wild-type and COX-2/ mice.
The NO donor sodium nitroprusside (SNP) restored recovery in
arteries from eNOS/ mice, and this was inhibited by aldosterone.
Actinomycin-D abolished the effect of aldosterone, indicating a
genomic effect. The effect was blocked by indomethacin and by the
COX-1 inhibitor valeryl salicylate but not by NS-398 (106 mol/l) or
the TP-receptor antagonist S18886 (107 mol/l). The effect of aldo-
sterone on recovery in arteries from wild-type mice and the SNP-
mediated dilatation in arteries from eNOS/ mice was inhibited by
the histamine H2 receptor antagonist cimetidine. RT-PCR showed
expression of mast cell markers in mouse mesenteric arteries. The
adventitia displayed granular cells positive for toluidine blue vital
stain. Confocal microscopy of live mast cells showed loss of quina-
crine fluorescence and swelling after aldosterone treatment, indicating
degranulation. RT-PCR showed expression of mineralocorticoid re-
ceptors in mesenteric arteries and in isolated mast cells. These
findings suggest that aldosterone inhibits recovery by stimulation of
histamine release from mast cells along mesenteric arteries. The
resulting activation of H2 receptors decreases the sensitivity to NO of
vascular smooth muscle cells. Aldosterone may chronically affect
vascular function through paracrine release of histamine.
mast cells; mineralocorticoid; endothelial function; microcirculation
CHANGES IN INTERNAL VASCULAR diameter and thus local periph-
eral resistance contribute to the regulation of arterial blood
pressure and the distribution of blood flow to distal tissues. In
renal arterioles, depolarization-elicited vasoconstriction is
counter-regulated by a secondary, nitric oxide (NO)-mediated
dilatation termed recovery (38). This phenomenon is associ-
ated with transfer of a calcium signal from the smooth muscle
cells to the endothelial cells. Another type of rapid interference
with vasoconstrictor responses occurs after 5 min of exposure
to aldosterone, which inhibits depolarization-induced constric-
tion in the afferent arteriole also in a NO-dependent manner
(37). Longer (50 min) exposure of renal arterioles to aldoste-
rone significantly inhibits recovery (37).
Aldosterone, whether circulating in the blood or produced
locally, exerts its effect on blood vessels by activating miner-
alocorticoid receptors (MR), which are present both in endo-
thelial and vascular smooth muscle cells (10, 15). However, the
vascular effects of aldosterone are complex and include both
vasodilator responses through NO formation (19, 37) and
vasoconstrictor effects due to intracellular calcium mobiliza-
tion (3, 23), whereby the net effect probably depends on the
level of oxidative stress (32). MR activation has classical
genomic effects or causes acute nongenomic responses. Two
types of nongenomic effects of aldosterone, mediated by MR,
have been reported in the vasculature: vasodilatation through
activation of phosphoinositide 3-kinase and endothelial NO
synthase (eNOS) (37) and vasoconstriction mediated by stimu-
lation of protein kinase C (3, 4). Both the dilator and constrictor
effects of aldosterone can be present within the same blood vessel
as illustrated by previous work in renal arterioles (37).
The preponderance of constrictor versus dilator responses to
aldosterone could be involved in the detrimental vascular
actions of the hormone. Indeed, in congestive heart failure
aldosterone levels are correlated with 6-mo mortality (33), and
inhibition of aldosterone action results in a 30% reduction in
mortality rate in patients with heart failure after myocardial
infarction (26). These clinical observations underline the sub-
stantial adverse effects of aldosterone on cardiovascular func-
tion. In particular, in pathophysiological situations character-
ized by high circulating levels of aldosterone (e.g., acute
myocardial infarction or heart failure), the risk of developing
spasms of the small arteries would increase if the constrictor
effect of aldosterone dominates and NO-mediated recovery is
reduced.
The mechanism underlying the blunting by aldosterone of
vasodilatation recovery is not clear. The present study was
designed to test the hypothesis that the procontractile effect of
long-term treatment with aldosterone observed in renal arteri-
oles of the rabbit is a more general phenomenon in blood
vessels and can be evoked in mouse arteries and that it involves
suppression of NO release combined with local production of
vasoconstrictor mediators.
METHODS
Animals. Animal care followed the guidelines of National Institutes
of Health, and the protocol was approved by the Danish Animal
Experiments Inspectorate under the Danish Ministry of Justice. Stud-
ies were conducted in male and female C57Bl/6J [wild-type (WT)]
mice (Taconic Farms, Ry, Denmark) in eNOS knockout (eNOS/)
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mice and cyclooxygenase (COX)-2/ (both strains from Jackson
Laboratories). Mice had free access to rodent chow (Altromin, Lage,
Germany) and tap water.
Isolation and microperfusion of mesenteric resistance arteries. The
mice were euthanatized by a blow to the head followed by decapita-
tion. Secondary mouse mesenteric arteries were dissected and trans-
ferred to a thermostated chamber (Warner Instruments, Hamden, CT).
The specimen was mounted in a set of glass pipettes and pressurized
to 60 mmHg at the inlet and 55 mmHg at the outlet, resulting in
perfusion with physiological saline solution (PSS) at a flow rate of 1
to 2 l/min, which mimics the in vivo conditions. The chamber was
mounted on an inverted microscope (Zeiss Axiovert 10, Oberkochen,
Germany). All experiments started with a 30-min period of equilibra-
tion at 37°C after the perfusion was established, and viability was
tested by administration of a high potassium solution (70 mmol/l, high
K) to the organ chamber. The inclusion criteria were 50% constric-
tion followed by 10% subsequent dilatation (recovery) except in
eNOS/ mice where the NO donor sodium nitroprusside (SNP) was
used to simulate recovery. Phentolamine (105 mol/l) was added to all
solutions to exclude nerve-mediated -adrenergic effects of depolar-
ization. In all experimental protocols pharmacological inhibitors were
added for 30 min followed by 50 min of incubation with aldosterone
plus inhibitor. The effect on recovery was tested by adding high K
on top of aldosterone and the inhibitor. The experiment was concluded
by testing the response to high K after a washout period. In another
series of experiments SNP was added 60 s after starting stimulation
with high K with and without aldosterone treatment. Also the effect
of 30-min treatment with increasing concentrations of histamine on
recovery was determined.
Data analysis. The experiments were recorded using a Till Photo-
nics video (Munich, Germany) camera and software. Images were
transferred to custom made imaging software [FluoroFix, University
of Southern Denmark (1)], and luminal diameter was determined at
the most reactive part of the blood vessel. Recovery represents the
difference in diameter from maximal constriction to the diameter after
dilatation, which was measured 30 s after maximal constriction for
preparations from WT and COX-2/ mice. For preparations from
eNOS/ mice diameter after recovery was measured at the end of the
SNP administration.
Reverse transcription-PCR. Mouse peritoneal mast cells were iso-
lated by injection of 5.0 ml isolation buffer containing (in mM) 140
NaCl, 4.7 KCl, 1.2 MgSO4, 1.0 CaCl2, 5.5 glucose, 10 HEPES, and
200 IE/ml heparin into the peritoneal cavity. After gentle massage the
cell suspension was collected and centrifuged at 1,000 rpm for 10 min
and the supernatant was discarded. Mouse mesenteric arteries were
cleaned of adhering connective tissue using small scissors. RNA was
isolated from either mesenteric arteries (75–150 ng/l RNA pr.
mouse) or mast cells by TRIzol reagent from Invitrogen (Carlsbad,
CA). RNA isolated from mast cells was treated with 3 units/mg RNA
of heparinase I (Sigma, St. Louis, MO) and RNasin (1 unit/ml;
Promega, Madison, WI) for 2 h at room temperature followed by
DNase I digestion (50 units DNaseI/gRNA; Fermentas, Glen Burnie,
MD). RNA from mast cells and mesenteric vessels was reverse
transcribed using Superscript and oligo (dT). RT-PCR analysis was
performed as described using 50 ng cDNA pr. PCR reaction (1).
RT-PCR consisted of 35 cycles, and each cycle included incubation at
95°C for 45 s, 60°C for 20 s (MCPT2), or 57°C for 45 s (MR) and
72°C for 45 s. Specific primers were used for the MR and the mast
cell-specific marker MCPT2. Primers were MR (Genbank NM_
001083906 sense 5=CTA GCA CAG TGG GGT CCA TT3= and
antisense 5=TTA GGG AAA GGA ACG TCG TG3=covering 148 base
pairs) and MCPT2 (Genbank NM_172044 sense 5=GCA CTT CTT
TTG CCT TCT GG 3= and antisense 5= TGT GCA GCA GTC ATC
ACA AA3= 170 base pairs). Negative controls included RNA where
no reverse transcriptase was added to the reaction (RT).
Morphological evaluation of mast cells in mesenteric arteries.
Mesenteric arteries with branches and arcade were dissected and fixed
by 4% (vol/vol) formaldehyde. To visualize mast cells, vessels were
stained in 0.1% toluidine blue for 10 min. Confocal microscopy was
used to evaluate morphological chances in mast cells adjacent to
mesenteric arteries after aldosterone stimulation. The confocal micro-
scope allowed using blood vessels surrounded by fat and peritoneal
membrane. To minimize movements the gut segment was removed.
Microdissected, formaldehyde fixated blood vessels and perfused
preparations were examined to ensure that mast cells were present
after dissection as well. To identify mast cells, the preparations were
loaded with the fluorescent dye quinacrine (106 M) at 20°C for 10
min (35). The arteries were incubated for 50 min at 37°C followed by
stimulation with aldosterone or vehicle for another 50 min at 37°C.
Confocal laser-scanning fluorescence microscopy (Olympus FV1000;
Olympus Denmark A/S, Ballerup, Denmark) was performed using an
Olympus water immersion objective (60; numerical aperture, 0.9).
The scanning area was set to 1,024  512 pixels without internal
zoom. Excitation was from a diode laser at 405 nm and fluorescence
monitored through a 426 nm long-pass filter.
Laser-scanning confocal microscopy with Fluo-4. To determine
whether or not aldosterone changes the calcium mobilization in
endothelial cells, the intracellular calcium concentration was mea-
sured during stimulation with acetylcholine. The intracellular calcium
concentration was measured at rest and acetylcholine stimulation,
with or without aldosterone incubation (109 mol/l, 50 min). For
imaging [Ca2]i dynamics, 4 M Fluo-4-AM (Molecular Probes/
Invitrogen; Carlsbad, CA) in PSS with 2.5% dimethylsulfoxide was
perfused through the vessel lumen for 45 min to load endothelial and
smooth muscle cells. Excess dye was washed off, and each blood
vessel was equilibrated in PSS for 45 min to allow for deesterification
of dye. Confocal laser-scanning fluorescence microscopy was per-
formed using an Olympus water immersion objective (20; numeri-
cal aperture, 0.5). The scanning area was set to 512  128 pixels
without internal zoom, corresponding to 873 m  218 m. Full-
frame imaging was performed at 2 Hz using excitation from an argon
laser at 488 nm with fluorescence monitored through a 505 nm
long-pass filter. The focal plane of the microscope was positioned
along the surface of the artery to visualize endothelial and smooth
muscle fluorescence simultaneously. The laser power was adjusted
(transmissivity 20%; photomultiplier tube voltage 450–550 V) to
obtain images with a mean intensity of 1,500 arbitrary intensity units
(range 200–4,095). This ensured fluorescence acquisition over the
full dynamic range of Fluo-4 without pixel saturation or excessive
photobleaching. Data are presented as the relative fluorescence inten-
sity change (F/F0), where F0 equals the average fluorescence intensity
before stimulation (36).
Chemicals. Phentolamine, HEPES, SNP, ACh, Toluidine Blue O,
indomethacin, aldosterone, quinacrine, cimetidine, and pyrilamine
were from Sigma-Aldrich. Valeryl salicylate and NS 398 were from
Cayman Chemical (Ann Arbor, MI). S18886 was a kind gift of the
Institut de Recherches Servier, Suresnes, France. The use of blockers
and concentrations are all based on the specificity described on
IUPHAR homepage (IUPHAR-db.org).
Saline solutions. The physiological saline solution (PSS) used
contained (in mM) 115 NaCl, 25 NaHCO3, 1.2 MgSO4, 2.5 K2HPO4,
1.3 CaCl2, 5.5 glucose, and 10 HEPES. The high potassium solution
contained (in mM) 45 NaCl, 70 KCl, 25 NaHCO3, 1.2 MgSO4, 2.5
K2HPO4, 1.3 CaCl2, 5.5 glucose, and 10 HEPES. The solutions were
equilibrated with 5% CO2 in air resulting in a pH 7.4 with 0.1% and
1% BSA superfusate and perfusate, respectively.
Statistical analysis. Data are presented as means  SE. Signifi-
cance of changes was calculated by two-way ANOVA followed by
Tukey’s multiple comparison test and Students t-test for comparison
of two groups. P values less than 0.05 were considered to indicate
statistically significant differences.
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RESULTS
Inhibitory effect of aldosterone on recovery. In perfused
small mesenteric arteries of the mouse, elevating the extracel-
lular potassium concentration (high K, 70 mmol/l) caused
constriction (maximal after 15 s) followed by partial dilatation
after 45 s (recovery; Fig. 1A, control). The average basal
diameter of 54 perfused vessels from WT mice was 140  6
m. After washout of potassium, the diameter returned to
basal.
The effect of aldosterone (109 mol/l) on K-evoked con-
striction and recovery was assessed in small mesenteric arteries
from WT mice. After the initial potassium test (Fig. 1A,
control, before) aldosterone (109 mol/l) was added to the
superfusate for 50 min with no effect on basal diameter
(91.9 9.3 m to 92.5 8.8 m) or constriction to K (from
23.0  2.9% to 27.3  2.7% of initial resting diameter).
However, the subsequent dilatation after high potassium (re-
covery) was inhibited significantly by aldosterone treatment,
from 55.6  6.4% to 13.4  4.8% for control and aldosterone,
respectively (Fig. 1, A and B). After washout of aldosterone the
recovery returned to a level no different from before aldoste-
rone treatment (59.6  3.4%; Fig. 1A, control after). In three
experiments without aldosterone incubation the second recov-
ery was no different from the first and third recovery. When
normalized to control recovery, aldosterone reduced recovery
to 24.4  5.6% (Fig. 2A). Incubation with the transcription
inhibitor actinomycin D (106 mol/l) alone had no effect on
K-induced vasoconstriction (data not shown), whereas K-
induced vasoconstriction was inhibited significantly by prein-
cubation with actinomycin D plus aldosterone (Fig. 1B). There
was no significant recovery in the presence of actinomycin D
plus aldosterone (Fig. 1B).
Involvement of NO. In mesenteric arteries from eNOS/
mice, the initial recovery was reduced significantly compared
with WT and the blood vessels did not dilate further over 3
min. The NO donor SNP (107 mol/l) was added 60 s after
start of stimulation with 70 mmol/l K. SNP dilated the vessel
to a similar extent as the secondary dilatation after high
potassium seen in the WT mice preparations (Fig. 1C). After
incubation with aldosterone (109 mol/l), the SNP-induced
dilatation was reduced to the same level as in the control
situation for arteries of eNOS/ mouse (Fig. 1C).
Involvement of COX-1. Incubation with the nonselective
COX inhibitor indomethacin (106 mol/L) had no significant
effect by itself on recovery but abolished the aldosterone (109
mol/l)-mediated reduction in recovery (Fig. 2B).
The preferential COX-2 inhibitor NS 398 (106 mol/l) had
no effect on inhibition of recovery by aldosterone (Fig. 2C).
Furthermore, aldosterone reduced recovery significantly in
small mesenteric arteries from COX-2/ mice (Fig. 2D), and
this response was not significantly different from that ob-
served in preparations from WT mice. Treatment of the
latter with the COX-1 selective inhibitor valeryl salicylate
(3  106 mol/l) did not abolish but attenuated significantly
the inhibitory effect of aldosterone on recovery (Fig. 2E vs.
2A). The thromboxane A2 receptor antagonist S18886 (Fig.
2F, 107 mol/l) had no significant effect on the inhibition of
recovery by aldosterone. In all experiments the statistical
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Fig. 1. Recovery and aldosterone. A: chances
in diameter in small mesenteric arteries from
wild-type (WT) mice during stimulation with
K (70 mM; control before) and after aldo-
sterone (109 M, 50 min) and after washout
of aldosterone (control after). B: diameter at
maximal constriction elicited by K (70
mM; black columns) and after recovery
(white columns). Control, initial stimulation;
Aldo, stimulation after incubation with aldo-
sterone; Aldo  Act D, stimulation after
incubation with the transcription inhibitor
actinomycin D (106 M); and aldosterone.
C: changes in diameter in small mesenteric
arteries from endothelial nitric oxide syn-
thase (eNOS)/ mice. Stimulation with K
followed by sodium nitroprusside (SNP 107
M) and SNP  Aldo, K, and addition of
SNP after incubation with aldosterone is
shown. D: recovery in small mesenteric ar-
teries from eNOS/ mice. Control, stimu-
lation with K; SNP, K and addition of
SNP (107 M); and SNP  Aldo, K and
addition of SNP after incubation with aldo-
sterone. Data are mean values  SE (n  6
in each group). *P  0.05.
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power attained were over 0.92 except for the valeryl salic-
ylate experiment with power of 0.59.
Involvement of histamine. The histamine receptor H1 antag-
onist pyrilamine (105 mol/l; Fig. 3A) and the selective H3
antagonist thioperamide (107 mol/l; Fig. 3B) did not signifi-
cantly alter the effect of aldosterone on recovery (Fig. 3, A and
B). By contrast, the histamine H2 receptor antagonist cimeti-
dine (104 mol/l; Fig. 3C; n  6) abolished it. In mesenteric
arteries from eNOS/ mice, the inhibition of SNP-induced
dilatation by aldosterone was abolished similarly by cimetidine
(Fig. 3D, n 6, compared with Fig. 1C). Statistical power over
0.84 was attained in all experiments. Pretreatment of arteries
with increasing concentrations of histamine (1011–108
mol/l) significantly reduced recovery in a manner similar to the
effect of aldosterone (Fig. 3E, n  6).
Histamine-storing cells in the vascular wall. Toluidine blue
staining of living arteries showed granular cells within the
adventitia that accumulated the vital dye in a way consistent
with mast cells (Fig. 4A). Some of the labeled cells were partly
degranulated and were metachromatically stained. Further-
more, PCR analysis revealed cDNA products of the expected
molecular size for the mast cell-specific marker MCPT2 in
isolated mesenteric arteries (Fig. 4B). The presence of granu-
lated cells was corroborated by staining with the fluorescent
dye quinacrine in dissected, perfused arteries (Fig. 4C) and in
nondissected blood vessels surrounded by fat and peritoneum
(Fig. 4, D and E). The putative mast cells located in situ were
labeled with quinacrine, and epifluorescence recordings were
obtained (Fig. 4D) before and after aldosterone treatment
(109 mol/l, 50 min, at 37°C; Fig. 4E). After aldosterone
treatment the cells appeared swollen and degranulated as
judged by the disappearance of the fluorescence quinacrine
signal.
MRs. PCR analysis showed expression of MR RNA in
peritoneal mast cells and mesenteric arteries (Fig. 4B).
Intracellular calcium. In perfused mesenteric arteries from
WT mice, ACh (106 mol/l) significantly increased fluores-
cence reflecting increased calcium concentration in the en-
Fig. 2. Involvement of prostaglandins in the
effect of aldosterone on recovery. Recovery is
shown relative to that observed after the initial
potassium induced constriction (control). A: con-
trol and after aldosterone (109 M, Aldo) (n
6). B: control and after aldosterone in the
presence of the cyclooxygenase (COX) inhib-
itor indomethacin (Aldo  Indo) (n  6).
C: control and aldosterone in the presence of
the preferential COX-2 inhibitor NS398
(NS  Aldo, n  6). D: recovery in small
mesenteric arteries from COX-2/ mice.
Control and after aldosterone (Aldo) (n  4).
E: control and after aldosterone in the presence
of the selective COX-1 inhibitor valeryl salic-
ylate (Val Aldo, n 6). F: control and after
aldosterone M in the presence of the throm-
boxane receptor antagonist S18886 3 * 107
M (S18886  Aldo) (n  6). Data are mean
values SE. *P 0.05; **P 0.01; ***P
0.001.
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dothelial cells (Fig. 5). After washout, the fluorescence
signal returned to baseline value. Aldosterone pretreatment
for 50 min did not alter the ACh-induced increase in
fluorescence.
DISCUSSION
The current study provides novel evidence that prolonged
exposure to aldosterone, at a concentration that mimics the
plasma aldosterone levels (1–50 nM) reported in mice (20) and
in upright humans receiving a normal or a low-salt diet (17),
has a procontractile effect on blood vessels through inhibition
of NO-mediated vasodilatation (recovery). This effect depends
on mast cell-derived histamine acting on histamine H2 recep-
tors. Furthermore, the inhibitory effect of aldosterone on vas-
cular relaxation involves prostaglandin production through
COX-1. In addition, the data show that aldosterone also coun-
teracts vasoconstriction through a nongenomic mechanism, as
previously reported in rabbit renal afferent arterioles (37).
The reduced recovery observed in vessels from eNOS/
mice indicates that recovery is NO-dependent in the mesenteric
artery, which is in agreement with pharmacological studies in
rabbit renal afferent arterioles (37). Dilatation in response to
the NO donor SNP was attenuated by aldosterone in arteries
from eNOS/ mice, indicating an effect of aldosterone,
which is distal to the formation of NO (37). Since aldosterone
inhibits the effect of SNP, the effect on recovery is likely to
attenuate the effect of NO on the target smooth muscle cells.
Chronic aldosterone treatment of Wistar-Kyoto rats and
spontaneous hypertensive rats induced endothelial dysfunction
and diminished relaxation to ACh (41). This effect was inhib-
ited by blockers of cyclooxygenases and a TP receptor antag-
onist (SQ29548). In the present study, COX-1-derived prosta-
Fig. 3. Involvement of histamine in the ef-
fect of aldosterone on recovery. A: recovery
in the initial test (control) and after aldoste-
rone (109 M) and the histamine H1 receptor
antagonist pyrilamine (105 M) (Aldo 
Pyr). B: recovery in the initial test (control)
and after aldosterone M and histamine re-
ceptor H3 antagonist thioperamide (107 M)
(Aldo  Thio). C: recovery in the initial test
(control) and after aldosterone in the pres-
ence of histamine H2 receptor antagonist
cimetidine (104 M) (Aldo  Cim). D: in-
volvement of histamine in the effect of al-
dosterone on recovery in small mesenteric
arteries from eNOS/ mice. Stimulation
with K (70 mM) (control), K and addition
of SNP after cimetidine (SNP  Cim), and
K and addition of SNP (107 M) after
incubation with aldosterone 50 min in the
presence of cimetidine (SNP  Cim 
Aldo). E: effect of increasing concentrations
of histamine (1011–108 M, hist-11- hist-8)
on recovery. Recovery in the initial test
(stimulation with K, control) is compared
with recovery after preincubation with his-
tamine. Data are mean values  SE (n  6).
*P  0.05; **P  0.01; ***P  0.001.
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glandins appear to be involved in the aldosterone-mediated
inhibition of recovery, whereas COX-2 is apparently not es-
sential for the effect. Furthermore, TP receptors appear not to
be involved in the effect of aldosterone since 107 mol/l of the
selective TP antagonist S18886 (31) did not prevent the blunt-
ing by aldosterone of recovery. The tested inhibitors of COX
enzymes were all used in concentrations above their IC50
value, and we therefore expect inhibition of the respective
enzymes to average more than 50%.
Histamine is released from mast cells and influences tissue
blood flow. However, it can promote both arteriolar dilatation
(29, 39) and vasoconstriction (30). In particular, histamine
evokes a biphasic response in arterioles from WT mice and a
constrictor response in the eNOS/ mouse (25). Mast cells
are present along resistance arteries from the hamster cheek
pouch (8), and they influence vascular resistance by releasing
histamine and thromboxane A2 (31). Mast cells are also present
in small mesenteric arteries (17). The aldosterone-induced
morphological changes of the mast cells adjacent to mesenteric
arteries observed here are similar to the changes seen after
stimulation of degranulation by ATP (6) or compound 48/80
(7). In the present study, the fluorescent staining with quina-
crine almost disappeared after aldosterone treatment and MRs
are expressed in mast cells of the mouse. Furthermore cimeti-
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Fig. 4. A: Toluidine blue staining of mast
cells (arrows) are located on the outside of
dissected arterioles. B: RT-PCR amplifica-
tion of cDNA from mesenteric arteries (Mes
Art) and mast cells for mineralocorticoid re-
ceptor (MR), mast cell protease-2 (MCPT2),
and b-actin. Negative control was mast cells-
RT: omission of reverse transcriptase during
reverse transcription. C: quinacrine staining
of isolated perfused mesenteric artery with
mast cells (blue) on the outside of the vessel.
D and E: morphological change in mast cell
after incubation with aldosterone (109 M)
for 50 min. Cells are located close to the wall
of a mesenteric artery. D: mast cells after
control period of 50 min at 37°C. E: same
cells as in D after incubation with aldoste-
rone for 50 min at 37°C. Note degranulation
and disappearance of fluorescent staining
(blue) with quinacrine (n  3). Bars repre-
sent 20 m.
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dine also blocked the effect of aldosterone on the dilatation
induced by the NO donor SNP. Taken in conjunction, these
observations indicate that aldosterone causes histamine release
via activation of MRs in adjacent mast cells and that the
released histamine in turn mediates inhibition of recovery.
Actinomycin D inhibits the release of histamine from rat
peritoneal mast cells evoked by known stimulators (substance
P, compound 48/80, and the calcium ionophore A23187) (13).
These earlier findings explain why in the present study actino-
mycin D prevented the inhibition of the aldosterone-mediated
effect on recovery. Likewise, prostaglandin E2 potentiates
histamine release (40) and indomethacin inhibits degranulation
of isolated rat peritoneal mast cells (11,18). The inhibition by
indomethacin on the effect of aldosterone on recovery may be
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Fig. 5. Effect of aldosterone on calcium response to ACh in endothelial cells. A, left: endothelial [Ca]i shown as relative fluorescence before (top) and after
(bottom) incubation with aldosterone. S, stimulation with ACh; WO, washout. A, right: images of an arteriole at rest (rest) and at maximal stimulation (max).
Inserted pictures show representative endothelial cells. B: relative fluorescence at rest, stimulation, and after washout in control situation and after incubation with
aldosterone (Aldo). Data are mean values  SE. *P  0.05; **P  0.01; ***P  0.001 aldosterone (109 M, 50 min, n  5).
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due to a similar effect on the mast cells localized in the
vascular wall.
Vascular responses to histamine are mediated through H1
and H2 receptor subtypes (12), and the dissected mesenteric
arteries contained both histamine H1 and H2 receptor mRNA
(data not shown). Histamine H2 receptors are present in cul-
tured smooth muscle cells (28). In human radial and internal
thoracic arteries, histamine evokes constriction and its concen-
tration-response curve is shifted to the right by H2 receptor
antagonists (5). In the present study, the H2 receptor antagonist
cimetidine abolished the effect of aldosterone on recovery,
whereas the H1 antagonist pyrilamine (105 mol/l) did not. The
histamine receptor antagonists were used in concentrations 10
to 100 times above the pKi (12), and we therefore assume that
more than 50% of the receptors are occupied with the antag-
onist. Cimetidine at the used concentration (104 M) might not
be selective toward H2 over H3 (12), but the selective H3
antagonist thioperamide in the concentration used (12) did not
prevent the effect of aldosterone. Thus the inhibitory effect of
cimetidine can reasonably be attributed to its blocking proper-
ties at H2 receptors. Furthermore, cimetidine blocked not only
the inhibitory effect of aldosterone per se on recovery but also
that induced by addition of SNP. Thus the procontractile effect
of aldosterone leading to blunting of the recovery vasodilata-
tion is likely to occur downstream of the release on NO rather
than by interfering with the latter. An increase in the intracel-
lular calcium concentration in the endothelial cells, leading to
the release of NO, is a part of the recovery after depolarization-
induced vasoconstriction in the renal afferent arteriole (38).
The increase in endothelial cell intracellular calcium after
stimulation of the small mesenteric arteries with the muscarinic
agonist was not decreased after incubation with aldosterone,
indicating that the endothelial cells can be stimulated as under
control conditions. These observations confirm that the effect
of aldosterone, and of the liberation of histamine that it must
cause, is downstream of the endothelial release of NO and on
the vascular smooth muscle cells. One possibility to explain the
lack of recovery induced by histamine released by degranulat-
ing mast cells could be phosphorylation of the smooth muscle
cell-specific protein CPI-17 via PKC activation resulting in
inhibition of myosin light chain phosphatase (9, 14).
Although the aldosterone effect observed in the present
study could be blocked by a histamine receptor antagonist, we
cannot rule of that aldosterone has also a direct effect on either
the vascular smooth muscle cells or the endothelial cells.
McCurley and colleagues (21), using mice with cell specific
deletion of MRs, have shown that MRs in smooth muscle cells
regulate vascular tone and arterial blood pressure indepen-
dently of the kidney, but only do so in aged mice. Furthermore,
overexpression of MRs in endothelial cells leads to an in-
creased arterial blood pressure (24). The present study was
performed in a vascular segment of resistance vessels as they
regulate peripheral vascular resistance; however, the response
to aldosterone may vary with artery size as arteries of different
size play different roles in the vasculature. The present data
from mesenteric small arteries suggest an additional indirect
new mechanism for aldosterone in the vasculature, whereby
the aldosterone-histamine pathway could be involved in the
detrimental effects of aldosterone on cardiovascular function.
Inhibition of recovery in arterioles would increase the risk of
ischemia/reperfusion injuries or necrosis of the distal tissue.
The potential increased incidence of microscopic necroses
would lead to accelerated degradation and decline of function
of the organs like the kidney or heart.
In summary, the present data indicate that aldosterone,
through COX-1, promotes degranulation of adventitial mast
cells in small mesenteric arteries. Histamine through vascular
H2 receptors attenuates the NO sensitivity of the smooth
muscle cell and antagonizes the normal rapid reopening of the
arterial lumen during vasoconstriction. To judge from the
measurements of endothelial calcium signals, the stimulus for
NO released by the endothelium was not attenuated by aldo-
sterone. Thus aldosterone inhibits NO-dependent recovery in
the small mesenteric arteries from the mouse by inducing
histamine release. This inhibition of recovery may represent a
blood pressure-independent adverse effect of aldosterone,
which contributes to the risk of developing vasospasm.
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